One assignee leads the ranking with 100 of the 770 records in scope, well ahead of the fifth-place holder at 34 and tenth place at 27. The top five assignees combined account for 33.8% of all records, and the top ten for 53.8%, showing a field where claim ownership is concentrated among a handful of established pharmaceutical and blood-product companies rather than spread evenly. Newer entrants mostly appear as single or few-filing entities in the long tail below that group.

Filings peaked at 97 in 2018 and have declined since, falling from 71 in 2021 to just 10 in 2024, an 86% drop over that three-year span. Because patent publication typically lags actual filing by around 18 months, the 2025 and 2026 figures in any dataset are still incomplete and should not be read as confirming a continued decline on their own. Based on the complete years available, however, the trend through 2024 is clearly downward from the 2018 peak.

Medicinal preparations (IPC class A61K) appear in 45.3% of the 770 records in scope, followed by microorganism and genetic engineering claims (C12N) at 38.3%, peptide and protein chemistry (C07K) at 37.4%, and sterilising or disinfecting methods (A61L) at 35.8%. Because a single patent record can carry several IPC classes, these percentages add up to more than 100% and should each be read against the full 770-record total rather than against one another. Separation and filtration processes (B01D) are comparatively minor at 9.7%.

This MIT filing, published mid-2023, covers a column-based continuous viral inactivation system using a pH feedback controller and/or a minimum residence time feedback controller to adjust feed flow rates, along with associated inactivation methods. Anyone building a feedback-controlled continuous inactivation process using pH or residence-time control to adjust flow should review this filing's specific claim language closely, since it sits in a comparatively thin area of the landscape compared to batch-hold chemistry. It does not appear to cover static batch-hold inactivation methods, which are claimed elsewhere in the dataset by longer-established assignees.

Relative to the dense claim coverage on core low-pH and solvent-detergent batch inactivation, areas such as continuous-flow inactivation control, detergent-free clearance alternatives, scale-down model validation, and mixing homogeneity sensing show thinner claim density in this dataset. These are process-engineering and validation branches rather than new inactivation chemistries, so a first claim there would likely centre on control methodology, sensor integration or validation protocol rather than a new inactivating agent. Given the sharp filing decline in the core chemistry since 2018, these adjacent branches are a more promising area to search before committing R&D resources.